Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study

doi:10.5527/wjn.v13.i4.98393

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (439)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

213

Figures (1-3)

Tables (1-2)

Sum=297

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=106

Publishing Process of This Article

Item

Count

Browse

Download

Sum=29

Dec 25, 2024 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Nephrol. Dec 25, 2024; 13(4): 98393
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98393

Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study

Mikhail Kostik, Inna Gaydukova, Damir Aliev, Olga Kalashnikova, Rinat Raupov, Maria Kaneva, Irina Chikova, Lyubov Sorokina, Natalia Lubimova, Ekaterina Gaidar, Eugenia Isupova, Elvira Kalashnikova

Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Olga Kalashnikova, Mikhail Kostik, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Sankt-Peterburg, Russia

Natalia Lubimova, Mikhail Kostik, Research Laboratory of Autoimmune and Autoinflammatory Diseases, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg 197341, Sankt-Peterburg, Russia

Rinat Raupov, Pediatric Rheumatology, H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery, Saint Petersburg 196603, Sankt-Peterburg, Russia

Damir Aliev, Inna Gaydukova, Department of Internal Medicine, Rheumatology, Examination of Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University, Saint Petersburg 191015, Sankt-Peterburg, Russia

Damir Aliev, Inna Gaydukova, Department of Rheumatology, Clinical Rheumatological Hospital #25, Saint Petersburg 190068, Sankt-Peterburg, Russia

Author contributions: Kostik MM, Kalashnikova EM, and Kalashnikova LS contributed to conceptualization of the study, and writing, review and editing of the manuscript; Kostik MM and Chikova IA contributed to the methodology; Aliev DB and Gaydukova IZ contributed software and resources, and contributed to the data curation; Kalashnikova OV, Isupova EA, Gaidar EV, and Kaneva MA contributed to the data validation; Lubimova NA and Raupov RK contributed to the formal data analysis; Sorokina LS contributed to the overall investigation and the data visualization; Kostik MM contributed to writing in original draft preparation of the manuscript, and provided funding, supervision, and project administration; All authors have read and agreed to the published version of the manuscript.

Supported by Ministry of Science and Higher Education of the Russian Federation, No. 075-15-2022-301; and the Russian Science Foundation Grant, No. 22-45-08004.

Institutional review board statement: The protocol of the study was approved by the local Ethical Committee of Saint Petersburg State Pediatric Medical University (# 1/3 from 11.01.2021).

Informed consent statement: Informed consent was obtained from all subjects involved in the study. All patients or patients’ representatives (for patients under the age of 15) gave their consent in their case report forms authorizing the anonymous use of their medical information. All patients were appropriately anonymized.

Conflict-of-interest statement: All authors declare no conflicts of interest.

Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Sankt-Peterburg, Russia. kost-mikhail@yandex.ru

Received: June 25, 2024
Revised: August 23, 2024
Accepted: September 5, 2024
Published online: December 25, 2024
Processing time: 134 Days and 21.6 Hours

Core Tip

Core Tip: Systemic lupus erythematosus in children is a severe life-threatening disease that requires systemic immune-suppressive therapy. Early biologic treatment in children with systemic lupus erythematosus can provide faster remission with a better corticosteroid-sparing effect.